Plasma infusion

CSL has expanded its Australian manufacturing capacity, opening a $230 million plant that will add 200 new jobs and generate $850 million worth of product each year.

The Australian biotechnology titan yesterday officially opened its advanced manufacturing facility at the CSL Behring site in Broadmeadows.

“CSL’s investment in Broadmeadows embeds the site into our global plasma manufacturing supply chain,” chief executive Paul Perreault said.

That supply chain now provided “lifesaving therapies to patients in more than 60 countries”, Mr Perreault said.

The new facility is designed to meet growing global demand for albumin – a protein derived from human plasma that is used in critical care to treat burns and shock.